LIBRE in the news
Brand building, advertising, digital
Tamtam found 20 recent articles about LIBRE.
- Blood Sugar on Garmin Fenix 9 Pro and Apple Watch Ultra 4 with Sugar Sense and Freestyle Libre
The article evaluates the Sugar Sense app and FreeStyle Libre 3 Plus sensor for monitoring blood sugar on smartwatches, detailing its benefits, limitations, and cost for both general users and athletes.
- Sugar Sense: Libre, Dexcom and Nightscout Glucose on Garmin
Sugar Sense offers Garmin Connect IQ apps to display live glucose data from FreeStyle Libre, Dexcom, and Nightscout directly on Garmin devices for athletes.
- The world's first dual-sensor CGM just got approved — FDA hails 'breakthrough' wearable for diabetes that could benefit 2.1 million Americans
The FDA approved the Libre Duo 10 Day CGM, the first wearable to simultaneously monitor ketone and blood sugar levels for diabetes management.
- FDA Authorizes First Ketone, Blood Sugar Monitor for Diabetes
The FDA authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, the first device to continuously monitor both ketone and blood sugar levels in diabetes patients.
- Trop de questions - Paysan Breton - LIBRE MullenLowe - agence Publicité / communication / 360
Paysan Breton launches a new yogurt and cottage cheese range with a TV and digital campaign created by agency LIBRE focusing on product quality and simplicity.
- Avec Paysan Breton et LIBRE, c’est toujours « au nom du bon » - Paysan Breton - LIBRE MullenLowe - agence Publicité / communication / 360
French butter brand Paysan Breton is debuting a new TV and digital campaign produced by agency LIBRE to promote its Guérande salt crystal butter.
- Abbott Flags Manufacturing Defect in FreeStyle Libre 3 Glucose Sensors
Abbott recalled millions of FreeStyle Libre 3 glucose sensors due to a defect causing inaccurate readings that risk patient safety, and is replacing affected units for free.
- FDA Warns 3 Million FreeStyle Libre 3 and Libre 3 Plus Sensors Impacted by Massive Abbott Recall
FDA recalls 3 million Abbott FreeStyle Libre 3 sensors due to inaccurate low glucose readings causing serious health risks and lawsuits.
- Abbott stock price watch: ABT heads into earnings week with Libre sensor recall on the radar
Abbott faces investor scrutiny ahead of Q4 earnings due to a Class I FDA recall of certain FreeStyle Libre 3 sensors linked to safety issues, while also launching new diabetes app features.
- FDA confirms recalls for Abbott CGM sensors—new lawsuit alleges company concealed information
FDA finalized recalls for Abbott's FreeStyle Libre 3 sensors due to faulty low glucose readings linked to serious injuries and deaths.
- Abbott FreeStyle Libre Lawsuit Alleges Recalled Glucose Monitor Led to Inaccurate Readings
Abbott recalled millions of FreeStyle Libre 3 glucose monitors after false readings caused serious health events and deaths, prompting a class action lawsuit.
- "Ça a changé ma vie" : les supérettes en libre-service Api font le pari de "redynamiser" les campagnes
Api runs self-service rural convenience stores in France to revitalize local commerce, growing rapidly but still unprofitable, aiming for break-even by 2027.
- The Bull Case For Abbott Laboratories (ABT) Could Change Following Libre Assist AI Launch In Diabetes Care
Abbott launched Libre Assist AI in its diabetes app to improve glucose management, supporting its growth in diabetes tech amid competitive pressures.
- Bold Raspberry-Infused Fragrances
Yves Saint Laurent introduced Libre Berry Crush Eau de Parfum, a raspberry-infused fragrance highlighting modern femininity.
- Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage
Abbott's Libre 3 Plus glucose sensor gains full public funding in Canada, while the company prepares for Q4 earnings amid mixed analyst outlooks and a major acquisition.
- Freestyle Libre 3 Lawsuit- Glucose Monitor Recall Lawsuit - January 2025
A recall of certain FreeStyle Libre 3 glucose sensors due to inaccurate low readings has caused serious health risks, injuries, and deaths, prompting legal investigations and user warnings.
- Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering
Abbott's new AI-driven Libre Assist boosts its digital diabetes offering amid steady stock momentum and analyst views suggesting the stock may be undervalued.
- Abbott Libre 3 Class Action Lawsuit Claims CGM Defects Could Result in Serious Injury
Abbott faces a class action lawsuit after recalling 3 million Freestyle Libre 3 glucose monitors due to dangerous false low readings causing serious injuries and deaths.
- A Look At Abbott Laboratories (ABT) Valuation After Libre Assist AI Diabetes Feature Launch
Abbott launched an AI-driven diabetes feature in its Libre app, with mixed analyst views on whether the stock is undervalued or overvalued.
- If You Have Diabetes, Libre Assist Uses AI to Predict Your Meal's Glucose Level
Abbott's Libre Assist uses AI to predict and help manage the glucose impact of meals for diabetics via the Libre app.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like LIBRE?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies